Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Total Liabilities (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Total Liabilities for 3 consecutive years, with $289.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 276.25% to $289.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $289.1 million through Dec 2025, up 276.25% year-over-year, with the annual reading at $289.1 million for FY2025, 276.25% up from the prior year.
  • Total Liabilities for Q4 2025 was $289.1 million at Nuvation Bio, up from $275.7 million in the prior quarter.
  • The five-year high for Total Liabilities was $289.1 million in Q4 2025, with the low at $16.0 million in Q1 2023.
  • Average Total Liabilities over 3 years is $100.7 million, with a median of $65.8 million recorded in 2024.
  • Peak annual rise in Total Liabilities hit 369.61% in 2024, while the deepest fall reached 19.37% in 2024.
  • Over 3 years, Total Liabilities stood at $16.4 million in 2023, then skyrocketed by 369.61% to $76.8 million in 2024, then surged by 276.25% to $289.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $289.1 million, $275.7 million, and $274.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.